AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2018
Jan 17, 2018
33422_dirs_2018-01-17_66e4c444-15e0-42fe-9f75-d723514c92a5.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-01-15
Reporting Person: TRABER PETER G (President & CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-01-15 | Stock option (right to buy) | $5.87 | A | 125000 | Acquired | 2028-01-15 | Common Stock (125000) | Direct |
Footnotes
F1: The options vest as follows: 25% immediately, 25% on June 30, 2018, and 50% on December 31, 2018.
More from GALECTIN THERAPEUTICS INC
Earnings Release
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21